News & Events

News

HITM-SURE: Phase Ib CAR-T hepatic artery infusion trial for stage IV adenocarcinoma using Pressure-Enabled Drug Delivery technology

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam cursus nec tortor et fermentum.

Fusce eu maximus urna.

Maecenas non pretium sem, nec vestibulum ante. 

Vestibulum convallis elit non ornare bibendum.

About TriSalus™ Life Sciences

TriSalus Life Sciences is committed to transforming outcomes for patients with pancreatic cancer and other solid tumors. Our solution is bold: to integrate novel and proprietary therapeutics with the TriSalus Pressure-Enabled Drug Delivery™ (PEDD™) technology. It’s a comprehensive approach intended to improve treatment response and, ultimately, outcomes.

The PEDD platform increases drug concentration in the tumor by generating favorable pressure to overcome the infusion barriers of the tumor microenvironment. The integration of PEDD with chemotherapy, immunotherapy, and other emerging therapies may improve treatment efficacy while reducing the toxicity challenges of traditional delivery methods.

Acknowledging that meaningful progress in this difficult-to-treat disease is not easy, we’re committed to transforming the battle with pancreatic cancer through deep science, novel technology innovation, and an absolute focus on the patient.

For more information, please visit www.trisaluslifesci.com.

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology (I-O) platforms, including key assets such as fully human antibodies (G-MAB™ library), clinical-stage immunocellular therapies (CAR-T), intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADCs), and clinical-stage oncolytic virus (Seprehvir®).

Sorrento’s commitment to life-enhancing therapies for cancer patients and osteoarthritis (OA) patients is also demonstrated by its effort to advance Resiniferatoxin (RTX), a first-in-class (TRPV1 agonist) nonopioid pain management small molecule, ZTlido® and SP-102, a nonopioid corticosteroid gel. Resiniferatoxin is completing a Phase 1b trial in terminal cancer patients and a Phase 1b trial for OA. ZTlido was approved by US FDA on 02/28/18. SP-102 (Semdexa™) is in Phase 3 pivotal study for the treatment of lumbar radicular pain/sciatica.

For more information, visit www.sorrentotherapeutics.com.
More information on Sorrento clinical trials can be found at www.clinicaltrials.gov.